YOLFTbeta
Adalta Ltd

Adalta Ltd

1AD · AU · Healthcare / Biotechnology

0.002AUD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.002
Open0.003
Day Range0.002 – 0.003
52-Week Range0.0017 – 0.008
Volume332.40K
Market Cap12.85M
P/E (TTM)0.00
Forward P/E0.00
EPS0.00
Dividend Yield0.00%
Beta0.19
50-Day Avg0.0033
200-Day Avg0.004

About

AdAlta Limited, a clinical-stage biotechnology company, develops cellular immunotherapies for the treatment of solid cancers in Australia. The company also commercializes protein therapeutics. In addition, it engages in the development of AD-21, a protein therapeutic for fibrotic diseases, including lung fibrosis and kidney fibrosis in Phase 1 clinical studies; and WD-34, a discovery stage i-body for the treatment and prevention of malaria and related diseases. The company was incorporated in 2006 and is based in Hawthorn East, Australia.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Timothy Charles Oldham B.Sc., BSc(Hons), L.L.B., LLB(Hons), Ph.D.
  • Employees2
  • Headquarters117 Camberwell Road, Hawthorn East, VIC, Australia, 3123, Australia
  • Websitehttps://www.adalta.com.au

Leadership

  • Dr. Timothy Charles Oldham B.Sc., BSc(Hons), L.L.B., LLB(Hons), Ph.D.CEO, MD & Director
  • Mr. Angus Tester Ph.D.Senior Director of Operations
  • Prof. Michael Foley Ph.D.Founding Chief Scientist
  • Dr. Andrew Peter O'Brien MBA., Ph.D.Head of Corporate Development · b. 1969
  • Ms. Janette DixonHead of Business Development
  • Dr. Kevin Patrick Lynch FFPM, M.D., MBBSConsultant Chief Medical Officer of Oncology · b. 1965
  • Mr. Cameron Peter Jones C.A.Company Secretary

Financials

Income Statement

Currency: AUD2012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue561.00K812.92K744.74K887.93K738.05K1.80M2.02M3.54M3.85M3.99M2.76M3.47M1.74M677.01K-
Growth (%)-+44.90%-8.39%+19.23%-16.88%+143.45%+12.43%+75.17%+8.71%+3.65%-30.90%+25.91%-49.91%-61.04%-
Cost of Revenue657.00K1.20M1.61M1.80M6845.43K3.14K32.50K7.01M7.01M260.61K29.92K229.88K219.51K-
Gross Profit--390.15K-865.41K-907.99K737.36K1.79M2.02M3.51M-6.40M848.19K987.94K3.44M1.51M457.50K-
Gross Margin--47.99%-116.20%-102.26%99.91%99.70%99.84%99.08%-166.28%21.27%35.86%99.14%86.77%67.58%-
Operating Expense-370.16K383.42K412.71K2.65M6.59M7.90M13.03M2.66M9.40M8.75M11.78M6.77M4.83M-
Operating Income--760.31K-1.25M-1.32M-1.91M-4.80M-5.88M-9.53M-9.05M-8.55M-7.76M-8.34M-5.26M-4.38M-4.80M
Operating Margin--93.53%-167.69%-148.74%-258.79%-267.16%-291.17%-269.24%-235.30%-214.54%-281.81%-240.42%-302.77%-646.48%-
EBITDA--759.06K-1.25M-1.32M-1.17M-3.00M-3.86M-9.38M-5.85M-5.50M-5.92M-7.58M-5.26M-4.45M-4.80M
EBITDA Margin--93.37%-167.54%-148.66%-158.70%-166.86%-191.01%-265.19%-152.05%-137.98%-214.74%-218.51%-302.77%-657.11%-
Net Income--760.30K-1.25M-1.31M-1.16M-2.83M-3.85M-5.92M-6.01M-5.63M-6.06M-4.85M-5.38M-4.50M-4.68M
Net Income Margin--93.53%-167.69%-147.29%-157.59%-157.65%-190.82%-167.24%-156.14%-141.16%-219.98%-139.84%-309.66%-665.02%-
R&D--------6.23M6.23M4.13M3.65M4.16M2.20M3.34M
R&D as % of Total Revenue--------162.04%156.33%149.81%105.11%239.51%324.35%-
Interest Expense00000059.80K115.55K115.55K97.64K111.39K123.75K115.00K62.35K290.94K
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%2.96%3.27%3.00%2.45%4.04%3.57%6.62%9.21%-

Balance Sheet

Currency: AUD2012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets1.21M607.75K459.76K967.07K10.73M8.09M4.44M9.31M6.91M9.05M10.65M7.73M5.57M2.14M1.72M
Total Liabilities178.00K323.83K286.95K261.18K114.13K344.51K366.32K1.82M3.21M2.66M5.27M5.82M3.54M2.74M1.35M
Total Equity1.03M273.20K172.82K705.89K10.62M7.75M4.07M7.49M3.70M6.39M5.38M1.91M2.03M-598.24K370.17K
Cash1.19M575.00K382.30K34.86K10.71M6.22M2.31M5.56M3.37M5.79M8.66M4.79M3.34M1.31M1.28M
Total Debt-------2.19M2.19M1.69M4.00M4.01M2.70M1.77M-
Net Debt--575.00K-382.30K-34.86K-10.71M-6.22M-2.31M-5.56M-1.18M-4.10M-4.66M-775.65K-635.10K462.02K-1.28M

Cash Flow

Currency: AUD2012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow--663.54K-1.29M-1.38M-1.17M-3.73M-3.93M-5.82M-5.89M-4.78M-4.09M-5.13M-5.26M-2.94M-4.44M
Investing Cash Flow---647-8.35K-8.35K-8.35K-3.14K-170.60K-2.38K-2.12K-25.23K-2.13K-62.40K109.61K-
Financing Cash Flow1.15M50.00K1.10M1.03M1.63M9.47M13.19K9.24M3.70M7.19M7.02M1.27M3.67M999.06K4.42M
Capital Expenditure2.00K02.30K6.75K6.75K6.75K3.14K170.60K2.38K2.12K25.23K2.13K62.40K30
Free Cash Flow--663.54K-1.29M-1.38M-1.17M-3.73M-3.93M-5.99M-5.89M-4.78M-4.11M-5.13M-5.32M-2.94M-4.44M
Dividends Paid--------3.55M5.18M2.76M----
FCF to OCF-100.00%100.18%100.00%100.00%100.18%100.08%102.93%100.04%100.04%100.62%100.04%101.19%100.00%100.00%
Dividend Paid to FCF---------60.24%-108.36%-67.02%----

Earnings

Report DateFeb 14, 2017Sep 7, 2017Feb 21, 2018Aug 28, 2018Feb 28, 2019Sep 8, 2019Feb 26, 2020Aug 27, 2020Feb 25, 2021Aug 26, 2021Feb 22, 2022Aug 28, 2022Feb 27, 2023Feb 20, 2025Aug 26, 2025
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.00--0.000.00
EPS Actual-0.03-0.01-0.030.00-0.03-0.02-0.040.00-0.020.00-0.01-0.01-0.010.00-0.03
Surprise---------------
Timing-----Pre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hours--

Key Statistics & Ratios

Market Cap12.85M
Enterprise Value11.70M
Trailing P/E0.00
Forward P/E0.00
Price / Sales31.78
Price / Book30.37
EPS0.00
Book Value0.00
Revenue (TTM)404.25K
Gross Profit (TTM)129.58K
EBITDA-4.31M
Profit Margin0.00%
Operating Margin-2250.98%
Return on Equity-62871.64%
Return on Assets-142.26%
Shares Outstanding3.21B
Shares Float1.38B
Beta0.19
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Dec 8, 20251:10